MNG370
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.441
- G2M_CHECKPOINT+0.388
- KRAS_SIGNALING_DN+0.313
- PANCREAS_BETA_CELLS+0.306
- SPERMATOGENESIS+0.266
- CHOLESTEROL_HOMEOSTASIS+0.239
- ANGIOGENESIS+0.192
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.154
- HYPOXIA+0.148
- MTORC1_SIGNALING+0.133
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.486
- DNA_REPAIR-0.460
- OXIDATIVE_PHOSPHORYLATION-0.414
- PROTEIN_SECRETION-0.411
- NOTCH_SIGNALING-0.406
- MYC_TARGETS_V1-0.400
- INTERFERON_GAMMA_RESPONSE-0.394
- ADIPOGENESIS-0.379
- TGF_BETA_SIGNALING-0.343
- UNFOLDED_PROTEIN_RESPONSE-0.338
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG159 | — | — | 0.843 |
| 2 | MNG835 | — | — | 0.838 |
| 3 | SRR6013484 | — | cohortA4 | 0.833 |
| 4 | MNG472 | — | — | 0.832 |
| 5 | MNG542 | — | — | 0.830 |
| 6 | MNG84 | — | — | 0.820 |
| 7 | SRR1797259 | — | cohortSC | 0.811 |
| 8 | TCGA-O2-A52W-01A-11R-A26W-07 | — | cohortSQ1 | 0.804 |
| 9 | 82982 | EPN | Supratentorial EPN | 0.790 |
| 10 | MDT-AP-0317 | Med | Medulloblastoma | 0.788 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 15 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.441 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.388 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.313 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.306 | Cobimetinib | — uncovered |
| SPERMATOGENESIS | 0.266 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.239 | Remibrutinib | — uncovered |
| ANGIOGENESIS | 0.192 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.154 | Inavolisib | — uncovered |
| HYPOXIA | 0.148 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.133 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.090 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.034 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.033 | Inavolisib | — uncovered |
| COAGULATION | 0.027 | Binimetinib | — uncovered |
| APICAL_SURFACE | 0.019 | Temsirolimus | — uncovered |